293 related articles for article (PubMed ID: 30704223)
61. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
62. 3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups.
Szuber N; Mudireddy M; Nicolosi M; Penna D; Vallapureddy RR; Lasho TL; Finke C; Begna KH; Elliott MA; Hook CC; Wolanskyj AP; Patnaik MM; Hanson CA; Ketterling RP; Sirhan S; Pardanani A; Gangat N; Busque L; Tefferi A
Mayo Clin Proc; 2019 Apr; 94(4):599-610. PubMed ID: 30824279
[TBL] [Abstract][Full Text] [Related]
63. Platelet activation and inhibition in polycythemia vera and essential thrombocythemia.
Patrono C; Rocca B; De Stefano V
Blood; 2013 Mar; 121(10):1701-11. PubMed ID: 23335367
[TBL] [Abstract][Full Text] [Related]
64. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
[TBL] [Abstract][Full Text] [Related]
65. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F.
Tefferi A; Elliott M
Semin Thromb Hemost; 2007 Jun; 33(4):313-20. PubMed ID: 17525888
[TBL] [Abstract][Full Text] [Related]
66. Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: the role of neutrophils.
Falanga A; Marchetti M; Barbui T; Smith CW
Semin Hematol; 2005 Oct; 42(4):239-47. PubMed ID: 16210037
[TBL] [Abstract][Full Text] [Related]
67. TET2 Mutation May Be More Valuable in Predicting Thrombosis in ET Patients Compared to PV Patients: A Preliminary Report.
Wang Z; Liu W; Wang D; Yang E; Li Y; Li Y; Sun Y; Wang M; Lv Y; Hu X
J Clin Med; 2022 Nov; 11(22):. PubMed ID: 36431092
[TBL] [Abstract][Full Text] [Related]
68. Pathophysiology and treatment of platelet-mediated microvascular disturbances, major thrombosis and bleeding complications in essential thrombocythaemia and polycythaemia vera.
Michiels JJ; Berneman ZN; Schroyens W; Van Vliet HH
Platelets; 2004 Mar; 15(2):67-84. PubMed ID: 15154599
[TBL] [Abstract][Full Text] [Related]
69. Expertise-based management in essential thrombocythemia and polycythemia vera.
Finazzi G; Barbui T
Cancer J; 2007; 13(6):372-6. PubMed ID: 18032974
[TBL] [Abstract][Full Text] [Related]
70. Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera.
Reikvam H; Tiu RV
Leukemia; 2012 Apr; 26(4):563-71. PubMed ID: 22076463
[TBL] [Abstract][Full Text] [Related]
71. High plasma levels of plasminogen activator inhibitor 1 (PAI-1) in polycythemia vera and essential thrombocythemia are associated with thrombosis.
Cancelas JA; García-Avello A; García-Frade LJ
Thromb Res; 1994 Sep; 75(5):513-20. PubMed ID: 7992252
[TBL] [Abstract][Full Text] [Related]
72. The Predictive Value of Neutrophil-Lymphocyte Ratio in Patients with Polycythemia Vera at the Time of Initial Diagnosis for Thrombotic Events.
Wang X; Tu Y; Cao M; Jiang X; Yang Y; Zhang X; Lai H; Tu H; Li J
Biomed Res Int; 2022; 2022():9343951. PubMed ID: 35978626
[TBL] [Abstract][Full Text] [Related]
73. Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review.
Ianotto JC; Curto-Garcia N; Lauermanova M; Radia D; Kiladjian JJ; Harrison CN
Haematologica; 2019 Aug; 104(8):1580-1588. PubMed ID: 30679326
[TBL] [Abstract][Full Text] [Related]
74. Aquagenic pruritus in essential thrombocythemia is associated with a higher risk of thrombosis.
Le Gall-Ianotto C; Le Calloch R; Couturier MA; Chauveau A; Lippert E; Carré JL; Misery L; Ianotto JC
J Thromb Haemost; 2019 Nov; 17(11):1950-1955. PubMed ID: 31344312
[TBL] [Abstract][Full Text] [Related]
75. It is time to change thrombosis risk assessment for PV and ET?
Passamonti F; Caramazza D; Mora B; Casalone R; Maffioli M
Best Pract Res Clin Haematol; 2014 Jun; 27(2):121-7. PubMed ID: 25189723
[TBL] [Abstract][Full Text] [Related]
76. Sex and age as prognostic factors in essential thrombocythemia.
Randi ML; Fabris F; Rossi C; Tison T; Barbone E; Girolami A
Haematologica; 1992; 77(5):402-4. PubMed ID: 1483589
[TBL] [Abstract][Full Text] [Related]
77. Essential thrombocythemia in young adults: major thrombotic complications and complications during pregnancy--a follow-up study in 68 patients.
Randi ML; Rossi C; Fabris F; Girolami A
Clin Appl Thromb Hemost; 2000 Jan; 6(1):31-5. PubMed ID: 10726046
[TBL] [Abstract][Full Text] [Related]
78. A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.
Mascarenhas J; Kosiorek HE; Prchal JT; Rambaldi A; Berenzon D; Yacoub A; Harrison CN; McMullin MF; Vannucchi AM; Ewing J; O'Connell CL; Kiladjian JJ; Mead AJ; Winton EF; Leibowitz DS; De Stefano V; Arcasoy MO; Kessler CM; Catchatourian R; Rondelli D; Silver RT; Bacigalupo A; Nagler A; Kremyanskaya M; Levine MF; Arango Ossa JE; McGovern E; Sandy L; Salama ME; Najfeld V; Tripodi J; Farnoud N; Penson AV; Weinberg RS; Price L; Goldberg JD; Barbui T; Marchioli R; Tognoni G; Rampal RK; Mesa RA; Dueck AC; Hoffman R
Blood; 2022 May; 139(19):2931-2941. PubMed ID: 35007321
[TBL] [Abstract][Full Text] [Related]
79. Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia.
Krecak I; Lucijanic M; Verstovsek S
Curr Hematol Malig Rep; 2022 Oct; 17(5):155-169. PubMed ID: 35932395
[TBL] [Abstract][Full Text] [Related]
80. Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis.
Bucalossi A; Marotta G; Bigazzi C; Galieni P; Dispensa E
Am J Hematol; 1996 May; 52(1):14-20. PubMed ID: 8638606
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]